Recent advances in laboratory-aided diagnosis of von Willebrand disease

Bibliography

• Sadler JE, Budde U, Eikenboom JC, et al. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006;4:2103-14
   PubMed Web of Science ®Google Scholar
• Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171-232
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011;37:425-6
   Web of Science ®Google Scholar
• Koutts J. A short history of diagnostic tests for von Willebrand disease: in memory of Barry Firkin (1930 to 2001) and Ted Zimmerman (1937 to 1988). Semin Thromb Hemost 2006;32:445-55
   PubMed Web of Science ®Google Scholar
• Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003;101:2089-93
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Diagnosing von Willebrand disease: a short history of laboratory milestones and innovations, plus current status, challenges, and solutions. Semin Thromb Hemost 2014;40:551-70
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Bonar RA, Meiring M, et al. Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res 2014;134:393-403
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Bonar R, Kershaw G, et al. (on behalf of the RCPA QAP in Haematology). Laboratory diagnosis of von Willebrand Disorder: Use of multiple functional assays reduces diagnostic error rates. Lab Hematol 2005;11:91-7
   PubMedGoogle Scholar
• Favaloro EJ, Bonar R, Kershaw G, et al. (on behalf of the RCPA QAP in Haematology). Reducing errors in identification of von Willebrand disease: The experience of the Royal college of Pathologists of Australasia Quality Assurance Program. Semin Thromb Hemost 2006;32:505-13
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Funk (Adcock) DM, Lippi G. Preanalytical variables in coagulation testing associated to diagnostic errors in hemostasis. Lab Med 2012;43:54-60
   Web of Science ®Google Scholar
• Favaloro EJ, Mehrabani PA, Koutts J. Laboratory assessment of von Willebrand factor: altered interpretation of laboratory data, and altered diagnosis of von Willebrand’s disease, as influenced by the use of different vWF assays and assay conditions. Clin App Thromb/Hemostas 1997;3:110-18
   Web of Science ®Google Scholar
• Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost 2014;40:17-27
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfus 2011;9(Suppl 2):s3-8
   PubMedGoogle Scholar
• Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Nat Acad Sci USA 1974;71:1906-9
   PubMed Web of Science ®Google Scholar
• Sporn LA, Chavin SI, Marder VJ, et al. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Inv 1985;76:1102-6
   PubMed Web of Science ®Google Scholar
• Hampshire DJ, Goodeve AC. The ISTH von Willebrand disease database: An update. Semin Thromb Hemost 2011;37:470-9
   PubMed Web of Science ®Google Scholar
• Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994;71:520-5
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Genetic testing for von Willebrand disease: the case against. J Thromb Haemost 2010;8:6-12
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Krigstein M, Koutts J, et al. Genetic testing for the diagnosis of von Willebrand Disease: benefits and limitations. J Coag Disorders 2010;2:37-47
   Google Scholar
• Von Willebrand Factor mutation database statistics. Available from: https://grenada.lumc.nl/LOVD2/VWF/variants_statistics.php/ [Last accessed 4 March 2015]
   Google Scholar
• Favaloro EJ. Rethinking the diagnosis of von Willebrand Disease. Thromb Res 2011;127S2:S17-21
   Google Scholar
• Othman M, Kaur H, Emsley J. Platelet-type von Willebrand disease: new insights into the molecular pathophysiology of a unique platelet defect. Semin Thromb Hemost 2013;39:663-73
   PubMed Web of Science ®Google Scholar
• Hamilton A, Ozelo M, Leggo J, et al. Frequency of Platelet type versus Type 2B von Willebrand Disease. An international registry-based study. Thromb Haemost 2011;105:501-8
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G, Favaloro EJ. Etiology and diagnosis of acquired von Willebrand syndrome. Clin Adv Hematol Oncol 2010;8:20-4
   PubMedGoogle Scholar
• Federici AB, Budde U, Castaman G, et al. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost 2013;39:191-201
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays. Blood Coagul Fibrinolysis 2011;22:553-64
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Bodó I, Israels SJ, Brown SA. von Willebrand disease and platelet disorders. Haemophilia 2014;20(Suppl 4):59-64
   PubMed Web of Science ®Google Scholar
• Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. Semin Thromb Hemost 2014;40:41-8
   PubMed Web of Science ®Google Scholar
• Nishino M, Girma J-P, Rothschild C, et al. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989;74:1591-9
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Mohammed S, Koutts J. Identification and prevalence of von Willebrand Disease type 2N (Normandy) in Australia. Blood Coag Fibrinolysis 2009;20:706-14
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Interaction of factor VIII and von Willebrand factor and the identification of type 2N von Willebrand disease. Thromb Res 2011;127:2-3
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Phenotypic identification of Platelet Type-von Willebrand disease and its discrimination from Type 2B von Willebrand disease: A question of 2B or not 2B? A story of non-identical twins? Or two-sides of a multi-denominational or multi-faceted primary haemostasis coin? Semin Thromb Hemost 2008;34:113-27
   PubMed Web of Science ®Google Scholar
• Hoyer LW, Shainoff JR. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood 1980;55:1056-9
   PubMed Web of Science ®Google Scholar
• Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost 2006;32:514-21
   PubMed Web of Science ®Google Scholar
• Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 2014;25:206-16
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Bonar R, Chapman K, et al. Differential sensitivity of von Willebrand factor ‘activity’ assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen binding and monoclonal antibody based assays. J Thromb Haemost 2012;10:1043-54
   PubMed Web of Science ®Google Scholar
• Adcock DM, Bethel M, Valcour A. Diagnosing von Willebrand disease: a large reference laboratory’s perspective. Semin Thromb Hemost 2006;32:472-9
   PubMed Web of Science ®Google Scholar
• Flood VH, Gill JC, Friedman KD, et al. Zimmerman Program Investigators. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem 2013;59:684-91
   PubMed Web of Science ®Google Scholar
• Chandler WL, Peerschke EIB, Castellone DD, et al. on behalf of the NASCOLA Proficiency Testing Committee. von Willebrand factor assay proficiency testing: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011;135:862-9
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Thom J, Patterson D, et al. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thromb Res 2009;123:862-8
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Thom J, Patterson D, et al. Potential supplementary utility of combined PFA-100 and functional VWF testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease. Blood Coag Fibrinolysis 2009;20:475-83
   PubMed Web of Science ®Google Scholar
• Kempfer AC, Silaf MR, Farias CE, et al. Binding of von Willebrand factor to collagen by flow cytometry. Am J Clin Pathol 1999;111:418-23
   PubMed Web of Science ®Google Scholar
• Mina A, Favaloro EJ, Koutts J. A novel flow cytometry single tube bead assay for quantitation of von Willebrand factor antigen and collagen-binding. Thromb Haemost 2012;108:999-1005
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Aboud M, Arthur C. Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor. American J Hematol 2001;66:53-6
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Mohammed S. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays. Thromb Res 2014;134:1292-300
   PubMed Web of Science ®Google Scholar
• Verfaillie CJ, De Witte E, Devreese KM. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease. Int J Lab Hematol 2013;35:555-65
   PubMed Web of Science ®Google Scholar
• Cabrera N, Moret A, Caunedo P, et al. Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method. Haemophilia 2013;19:920-5
   PubMed Web of Science ®Google Scholar
• Stufano F, Lawrie AS, La Marca S, et al. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia 2014;20:147-53
   PubMed Web of Science ®Google Scholar
• Costa-Pinto J, Pérez-Rodríguez A, del C Goméz-del-Castillo M, et al. Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies. Haemophilia 2014;20:559-67
   PubMed Web of Science ®Google Scholar
• de Maistre E, Volot F, Mourey G, et al. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance. Thromb Haemost 2014;112:825-30
   PubMed Web of Science ®Google Scholar
• Giannini S, Mezzasoma AM, Leone M, Gresele P. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand’s disease by flow cytometry. Haematologica 2007;92:1647-54
   PubMed Web of Science ®Google Scholar
• Chen D, Daigh CA, Hendricksen JI, et al. A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. J Thromb Haemost 2008;6:323-30
   PubMed Web of Science ®Google Scholar
• Hillarp A, Stadler M, Haderer C, et al. Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol. J Thromb Haemost 2010;8:2216-23
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010;8:2842-4
   PubMed Web of Science ®Google Scholar
• Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986;43:303-11
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen binding assay aids in the diagnosis of, and permits sensitive discrimination between, Type I and Type II von Willebrand’s disease. Blood Coagul Fibrinolysis 1991;2:285-91
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. von Willebrand factor (VWF) collagen binding (activity) assay (VWF:CBA) in the diagnosis of von Willebrand’s disorder (VWD): A 15-year journey. Semin Thromb Hemost 2002;28:191-202
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Collagen binding assay for von Willebrand Factor (VWF:CBA): Detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000;83:127-35
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. An update on the von Willebrand factor collagen binding (VWF:CB) assay: 21 years of age and beyond adolescence, but not yet a mature adult. Semin Thromb Hemost 2007;33:727-44
   PubMed Web of Science ®Google Scholar
• Ni Y, Nesrallah J, Agnew M, et al. Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity. Int J Lab Hematol 2013;35:170-6
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010;104:1009-21
   PubMed Web of Science ®Google Scholar
• Veyradier A, Caron C, Ternisien C, et al. Validation of the first commercial ELISA for type 2N von Willebrand’s disease diagnosis. Haemophilia 2011;17:944-51
   PubMed Web of Science ®Google Scholar
• Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996;88:2951-8
   PubMed Web of Science ®Google Scholar
• Sztukowska M, Gallinaro L, Cattini MG, et al. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol 2008;143:107-14
   PubMed Web of Science ®Google Scholar
• Schooten CJ, Tjernberg P, Westein E, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005;3:2228-37
   PubMed Web of Science ®Google Scholar
• Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008;111:4979-85
   PubMed Web of Science ®Google Scholar
• Millar CM, Riddell AF, Brown SA, et al. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations. Thromb Haemost 2008;99:916-24
   PubMed Web of Science ®Google Scholar
• Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008;111:3540-5
   PubMed Web of Science ®Google Scholar
• Eikenboom J, Federici AB, Dirven RJ, et al. MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood 2013;121:2336-9
   PubMed Web of Science ®Google Scholar
• Laffan MA, Lester W, O’Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014;167:453-65
   PubMed Web of Science ®Google Scholar
• Castaman G, Hillarp A, Goodeve A. Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis. Haemophilia 2014;20(Suppl 4):65-70
   PubMed Web of Science ®Google Scholar
• Goodeve AC, Pavlova A, Oldenburg J. Genomics of bleeding disorders. Haemophilia 2014;20(Suppl 4):50-3
   PubMedGoogle Scholar
• Perry DJ, Cumming T, Goodeve A, et al. The UK National External Quality Assessment Scheme for heritable bleeding disorders. Semin Thromb Hemost 2014;40:261-8
   PubMed Web of Science ®Google Scholar
• Bodó I, Eikenboom J, Montgomery R, et al. Subcommittee on von Willebrand factor. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lawrie AS, Stufano F, Canciani MT, et al. A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia 2013;19:338-42
   PubMed Web of Science ®Google Scholar
• Graf L, Moffat KA, Carlino SA, et al. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin. Int J Lab Hematol 2014;36:341-51
   PubMed Web of Science ®Google Scholar
• Geisen U, Zieger B, Nakamura L, et al. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo. Thromb Res 2014;134:246-50
   PubMed Web of Science ®Google Scholar
• Patzke J, Budde U, Huber A, et al. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. Blood Coagul Fibrinolysis 2014;25:860-70
   PubMed Web of Science ®Google Scholar
• Flood VH, Gill JC, Morateck PA, et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011;117:e67-74
   Google Scholar
• Goodall AH, Jarvis J, Chand S, et al. An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII:vWF) using a monoclonal antibody that defines a functional epitope. Br J Haematol 1985;59:565-77
   PubMed Web of Science ®Google Scholar
• Chand S, McCraw A, Hutton R, et al. A two-site, monoclonal antibody-based immunoassay for von Willebrand factor--demonstration that vWF function resides in a conformational epitope. Thromb Haemost 1986;55:318-24
   PubMed Web of Science ®Google Scholar
• McCraw A, Chand S, Tuddenham EG, et al. A monoclonal antibody based immunoradiometric assay for von Willebrand factor: survey of a large patient group. Thromb Res 1987;45:101-8
   PubMed Web of Science ®Google Scholar
• Murdock PJ, Woodhams BJ, Matthews KB, et al. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997;78:1272-7
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Detection of von Willebrand Disorder (VWD) and identification of qualitative von Willebrand Factor (VWF) defects: Direct comparison of commercial ELISA-based ‘VWF:Activity’ options. Am J Clin Pathol 2000;114:608-18
   PubMed Web of Science ®Google Scholar
• Favaloro EJ, Henniker A, Facey D, Hertzberg M. Discrimination of von Willebrands Disease (VWD) subtypes: Direct comparison of von Willebrand Factor:Collagen binding activity/assay (VWF:CBA) with Monoclonal Antibody (MAB) based ELISA VWF-detection systems. Thromb Haemost 2000;84:541-7
   PubMed Web of Science ®Google Scholar
• Sucker C, Senft B, Scharf RE, Zotz RB. Determination of von Willebrand factor activity: evaluation of the HaemosIL assay in comparison with established procedures. Clin Appl Thromb Hemost 2006;12:305-10
   PubMed Web of Science ®Google Scholar
• Salem RO, Van Cott EM. A new automated screening assay for the diagnosis of von Willebrand disease. Am J Clin Pathol 2007;127:730-5
   PubMed Web of Science ®Google Scholar
• Pinol M, Sales M, Costa M, et al. Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease. Haematologica 2007;92:712-13
   PubMed Web of Science ®Google Scholar
• Chen D, Tange JI, Meyers BJ, et al. Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay. J Thromb Haemost 2011;9:1993-2002
   PubMed Web of Science ®Google Scholar
• Hilbert L, Fressinaud E, Ribba AS, et al. INSERM network on molecular abnormalities in von Willebrand disease. Identification of a new type 2M von Willebrand disease mutation also at position 1324 of von Willebrand factor. Thromb Haemost 2002;87:635-40
   PubMed Web of Science ®Google Scholar
• Corrales I, Catarino S, Ayats J, et al. High throughput molecular diagnosis of von Willebrand disease by next generation sequencing methods. Haematologica 2012;97:1003-7
   PubMed Web of Science ®Google Scholar
• Lawrie AS, Kobayashi K, Lane PJ, et al. The automation of routine light transmission platelet aggregation. Int J Lab Hematol 2014;36:431-8
   PubMed Web of Science ®Google Scholar
• De Moerloose P, Reber G, Musial J, Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost 2010;8:1540-6
   PubMed Web of Science ®Google Scholar
• Chung Y, Kim JE, Lim HS, Kim HK. Clinical performance of anticardiolipin and antiβ2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods. Blood Coagul Fibrinolysis 2014;25:10-15
   PubMed Web of Science ®Google Scholar
• Meneghel L, Ruffatti A, Gavasso S, et al. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clin Chem Lab Med 2015;53(7):1083-9
   PubMed Web of Science ®Google Scholar
• Quiroga T, Goycoolea M, Panes O, et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007;92:357-65
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Clinical Utility of the PFA-100. Semin Thromb Hemost 2008;34:709-33
   PubMed Web of Science ®Google Scholar
• Kraus E, Kraus K, Obser T, et al. Platelet-free shear flow assay facilitates analysis of shear-dependent functions of VWF and ADAMTS13. Thromb Res 2014;134:1285-91
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Evaluating the interaction of von Willebrand factor and ADAMTS13 - and perhaps also beyond ADAMTS13. Thromb Res 2014;134:1167-8
   PubMed Web of Science ®Google Scholar